Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag

Prelude Therapeutics Incorporated

PRLD Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of PRLD by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
PRLD Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
PRLD Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
PRLD Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in PRLD holdings by institutional investors

Quarterly net insider trading by PRLD's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Former government officials who have lobbied for PRLD

2 former government officials from 1 congressional office at 1 lobbying firm have lobbied for PRLD, most recently Sep 25, 2025.

  • Richard Burr
    Margaret Martin Senate New Senior FDA Policy Advisor, Senate Health, Education, Labor and Pensions Committee; Health Policy Assistant, Sen. Richard Burr Formerly with Richard Burr · DLA PIPER LLP (US) · Sep 25, 2025
  • Preeya Noronha Pinto Executive New Acting General Counsel, Dept. of Health and Human Services Formerly Acting General Counsel, Dept. of Health and Human Services · DLA PIPER LLP (US) · Sep 25, 2025

PRLD Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard

PRLD Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
PRLD Income Statement
PRLD Balance Sheet
PRLD Cash Flow
U.S. Patents

New PRLD patent grants

  • Patent Title: Cdk inhibitors and their use as pharmaceuticals Dec. 02, 2025
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Nov. 04, 2025
  • Patent Title: Brm targeting compounds and associated methods of use Oct. 21, 2025
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Oct. 14, 2025
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Sep. 16, 2025
  • Patent Title: Cdk inhibitors and their use as pharmaceuticals Oct. 29, 2024
  • Patent Title: Cdk inhibitors and their use as pharmaceuticals Mar. 26, 2024
  • Patent Title: Brm targeting compounds and associated methods of use Jul. 18, 2023
  • Patent Title: Cdk inhibitors and their use as pharmaceuticals Jun. 27, 2023
  • Patent Title: Cdk inhibitors and their use as pharmaceuticals Jun. 13, 2023
  • Patent Title: Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (prmt5) Dec. 13, 2022
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Feb. 22, 2022
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Jan. 11, 2022
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Jan. 04, 2022
  • Patent Title: Selective inhibitors of protein arginine methytransterase 5 (prmt5) Dec. 28, 2021
  • Patent Title: Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein Sep. 28, 2021
  • Patent Title: Selective inhibitors of protein arginine methlytransferase 5 (prmt5) Aug. 03, 2021
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Jul. 14, 2020
  • Patent Title: Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Feb. 25, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to PRLD from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
PRLD News

Recent insights relating to PRLD

CNBC Recommendations

Recent picks made for PRLD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PRLD

PRLD Analyst Ratings

PRLD Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
PRLD Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $PRLD stock a Buy, Sell, or Hold?

  • What is the price target for $PRLD stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

PRLD Top Shareholders
Shareholder
Shares Held
PRLD Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $PRLD stock?

  • Who owns the most shares of $PRLD stock?

  • What funds own $PRLD stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

PRLD Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view PRLD Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About PRLD

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

  • Address Wilmington, DE
  • Market Cap 387.0 million
  • Employees 79
  • Industrial Classification Pharmaceutical Preparations

Prelude Therapeutics Incorporated (PRLD) Historical Stock Prices

Prelude Therapeutics Incorporated (PRLD) closed at $4.85 on September 22, 2026. Over the past year its adjusted close ranged from $1.01 to $6.63. Daily prices go back to September 25, 2020, 1,504 trading days in all.

  • 1 month-26.85%
  • 3 months+10.73%
  • Year to date+67.24%
  • 1 year+380.20%
  • 3 years+72.60%
  • 5 years-86.34%
  • Max-81.49%
See every congressional and insider trade on the PRLD price chart

Quiver Premium charts PRLD's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 22, 2026 4.70 4.91 4.63 4.85 4.85 424,586
Sep 21, 2026 4.88 4.91 4.69 4.70 4.70 392,656
Sep 18, 2026 4.58 4.87 4.51 4.87 4.87 1,165,142
Sep 17, 2026 4.79 4.91 4.49 4.57 4.57 533,876
Sep 16, 2026 4.55 4.65 4.36 4.47 4.47 191,572
Sep 15, 2026 4.56 4.58 4.40 4.52 4.52 263,317
Sep 14, 2026 4.60 4.68 4.50 4.59 4.59 275,344
Sep 11, 2026 4.72 4.75 4.56 4.59 4.59 520,540
Sep 10, 2026 5.04 5.22 4.64 4.67 4.67 562,215
Sep 9, 2026 5.25 5.34 5.06 5.09 5.09 311,983
Sep 8, 2026 5.38 5.46 5.19 5.30 5.30 257,890
Sep 4, 2026 5.19 5.52 5.19 5.46 5.46 400,285
Sep 3, 2026 5.44 5.62 5.11 5.25 5.25 577,964
Sep 2, 2026 5.53 5.82 5.30 5.43 5.43 355,093
Sep 1, 2026 5.55 5.61 5.25 5.49 5.49 538,439
Aug 31, 2026 5.39 5.63 5.24 5.60 5.60 737,667
Aug 28, 2026 6.27 6.38 5.42 5.47 5.47 725,232
Aug 27, 2026 6.48 6.61 6.21 6.34 6.34 364,363
Aug 26, 2026 6.61 6.71 6.37 6.56 6.56 466,282
Aug 25, 2026 6.57 6.70 6.31 6.59 6.59 415,482
Aug 24, 2026 6.64 6.83 6.12 6.47 6.47 515,716
Aug 21, 2026 6.56 6.82 6.40 6.63 6.63 519,206
Aug 20, 2026 5.70 6.65 5.70 6.50 6.50 2,438,831
Aug 19, 2026 5.84 5.90 5.66 5.78 5.78 421,547
Aug 18, 2026 5.62 5.78 5.49 5.75 5.75 268,552
Aug 17, 2026 5.57 5.86 5.45 5.63 5.63 265,426
Aug 14, 2026 5.45 5.61 5.15 5.55 5.55 452,138
Aug 13, 2026 5.77 5.91 5.21 5.36 5.36 888,274
Aug 12, 2026 5.39 5.90 5.39 5.73 5.73 623,877
Aug 11, 2026 4.95 5.85 4.83 5.32 5.32 698,441
Aug 10, 2026 4.91 5.00 4.81 4.83 4.83 217,169
Aug 7, 2026 4.74 4.92 4.63 4.90 4.90 165,697
Aug 6, 2026 4.47 4.75 4.47 4.68 4.68 242,342
Aug 5, 2026 4.51 4.59 4.37 4.54 4.54 158,284
Aug 4, 2026 4.41 4.58 4.41 4.52 4.52 218,840
Aug 3, 2026 4.65 4.65 4.35 4.39 4.39 288,744
Jul 31, 2026 5.03 5.15 4.57 4.60 4.60 292,738
Jul 30, 2026 4.71 5.13 4.71 5.05 5.05 329,782
Jul 29, 2026 4.64 4.98 4.31 4.71 4.71 485,705
Jul 28, 2026 4.55 4.87 4.19 4.64 4.64 1,859,004
Jul 27, 2026 3.86 4.04 3.86 3.89 3.89 179,539
Jul 24, 2026 3.95 3.95 3.77 3.83 3.83 284,205
Jul 23, 2026 3.84 3.96 3.77 3.93 3.93 205,866
Jul 22, 2026 4.02 4.07 3.90 3.92 3.92 171,127
Jul 21, 2026 4.03 4.21 4.01 4.04 4.04 145,565
Jul 20, 2026 4.24 4.32 3.95 4.06 4.06 284,125
Jul 17, 2026 4.08 4.31 4.01 4.20 4.20 180,697
Jul 16, 2026 4.43 4.43 4.03 4.18 4.18 405,789
Jul 15, 2026 4.38 4.55 4.31 4.46 4.46 211,223
Jul 14, 2026 4.48 4.54 4.35 4.39 4.39 325,465
Jul 13, 2026 4.73 4.73 4.41 4.44 4.44 320,592
Jul 10, 2026 4.92 4.98 4.35 4.80 4.80 577,888
Jul 9, 2026 5.14 5.33 4.84 4.91 4.91 309,649
Jul 8, 2026 4.96 5.28 4.88 5.12 5.12 282,567
Jul 7, 2026 4.96 5.06 4.65 4.97 4.97 320,073
Jul 6, 2026 4.92 5.13 4.84 4.99 4.99 241,292
Jul 2, 2026 4.83 5.21 4.82 4.91 4.91 326,571
Jul 1, 2026 5.32 5.44 4.77 4.91 4.91 554,245
Jun 30, 2026 4.90 5.69 4.90 5.33 5.33 829,625
Jun 29, 2026 4.28 4.99 4.28 4.93 4.93 477,977
Jun 26, 2026 4.08 4.38 4.02 4.38 4.38 3,693,041
Jun 25, 2026 4.40 4.40 4.02 4.10 4.10 375,186
Jun 24, 2026 4.36 4.50 4.25 4.27 4.27 232,425
Jun 23, 2026 4.25 4.42 4.12 4.38 4.38 454,277
Jun 22, 2026 4.13 4.45 4.13 4.32 4.32 296,671
Jun 18, 2026 4.38 4.64 4.16 4.32 4.32 1,076,626
Jun 17, 2026 4.20 4.43 4.07 4.35 4.35 317,739
Jun 16, 2026 4.48 4.48 4.09 4.20 4.20 450,507
Jun 15, 2026 4.60 4.69 4.42 4.46 4.46 327,389
Jun 12, 2026 4.03 4.52 3.97 4.49 4.49 315,409
Jun 11, 2026 3.95 4.13 3.89 4.11 4.11 204,867
Jun 10, 2026 3.93 4.11 3.88 3.95 3.95 192,717
Jun 9, 2026 3.87 4.04 3.76 3.94 3.94 235,360
Jun 8, 2026 3.86 4.00 3.76 3.84 3.84 281,283
Jun 5, 2026 4.05 4.06 3.74 3.81 3.81 220,942
Jun 4, 2026 3.66 4.19 3.61 4.08 4.08 399,893
Jun 3, 2026 3.49 3.72 3.40 3.66 3.66 375,938
Jun 2, 2026 3.76 3.76 3.47 3.50 3.50 384,979
Jun 1, 2026 3.90 4.00 3.81 3.82 3.82 237,803
May 29, 2026 3.93 4.00 3.76 3.92 3.92 288,208
May 28, 2026 4.13 4.13 3.80 3.93 3.93 373,746
May 27, 2026 4.14 4.38 4.10 4.16 4.16 170,883
May 26, 2026 4.14 4.31 4.03 4.09 4.09 311,102
May 22, 2026 4.37 4.52 4.16 4.27 4.27 241,676
May 21, 2026 4.40 4.53 4.31 4.33 4.33 220,604
May 20, 2026 4.30 4.54 4.12 4.50 4.50 386,110
May 19, 2026 4.27 4.47 3.95 4.27 4.27 404,341
May 18, 2026 4.44 4.75 4.26 4.34 4.34 463,520
May 15, 2026 4.33 4.60 4.10 4.48 4.48 472,174
May 14, 2026 4.62 4.67 4.40 4.47 4.47 263,581
May 13, 2026 4.57 4.81 4.42 4.66 4.66 393,292
May 12, 2026 4.80 4.98 4.55 4.64 4.64 309,912
May 11, 2026 4.85 5.14 4.75 4.80 4.80 343,725
May 8, 2026 5.15 5.32 4.79 4.86 4.86 528,314
May 7, 2026 4.88 5.31 4.65 5.15 5.15 547,755
May 6, 2026 4.78 5.05 4.32 4.84 4.84 708,212
May 5, 2026 4.82 5.13 4.65 4.67 4.67 417,576
May 4, 2026 4.82 4.92 4.50 4.74 4.74 722,999
May 1, 2026 5.18 5.26 4.50 4.70 4.70 1,106,178
Apr 30, 2026 4.52 5.23 4.27 5.23 5.23 586,775
Apr 29, 2026 4.31 4.37 4.04 4.27 4.27 454,123
Apr 28, 2026 4.53 4.76 4.17 4.39 4.39 406,986
Apr 27, 2026 4.92 5.08 4.43 4.52 4.52 586,688
Apr 24, 2026 4.88 4.88 4.43 4.70 4.70 865,216
Apr 23, 2026 4.33 4.42 3.89 4.40 4.40 717,328
Apr 22, 2026 4.66 4.73 4.28 4.31 4.31 321,056
Apr 21, 2026 4.69 4.99 4.48 4.62 4.62 389,833
Apr 20, 2026 5.09 5.50 4.50 4.51 4.51 982,448
Apr 17, 2026 4.50 4.51 4.10 4.44 4.44 367,363
Apr 16, 2026 5.50 5.51 4.21 4.43 4.43 830,826
Apr 15, 2026 4.34 5.54 4.26 5.52 5.52 978,037
Apr 14, 2026 4.48 4.48 4.27 4.40 4.40 204,664
Apr 13, 2026 4.11 4.48 4.01 4.37 4.37 177,929
Apr 10, 2026 4.43 4.62 4.08 4.08 4.08 194,745
Apr 9, 2026 4.46 4.46 3.83 4.40 4.40 233,533
Apr 8, 2026 4.50 4.82 4.19 4.22 4.22 397,806
Apr 7, 2026 3.68 4.50 3.68 4.40 4.40 690,039
Apr 6, 2026 3.51 3.90 3.48 3.68 3.68 391,151
Apr 2, 2026 3.30 3.66 3.27 3.46 3.46 105,677
Apr 1, 2026 3.45 3.69 3.44 3.45 3.45 139,943
Mar 31, 2026 3.14 3.58 3.14 3.42 3.42 188,543
Mar 30, 2026 3.10 3.21 3.01 3.07 3.07 176,047
Mar 27, 2026 3.23 3.32 3.01 3.05 3.05 119,078
Mar 26, 2026 3.20 3.31 3.12 3.24 3.24 72,356
Mar 25, 2026 3.15 3.40 3.15 3.26 3.26 99,847
Mar 24, 2026 3.06 3.30 3.06 3.12 3.12 200,427
Mar 23, 2026 3.06 3.23 2.92 3.16 3.16 164,083
Mar 20, 2026 3.12 3.24 2.83 2.99 2.99 339,141
Mar 19, 2026 3.09 3.44 3.08 3.19 3.19 191,058
Mar 18, 2026 3.43 3.43 3.04 3.12 3.12 97,769
Mar 17, 2026 3.40 3.60 3.37 3.43 3.43 138,984
Mar 16, 2026 3.35 3.70 3.23 3.36 3.36 256,078
Mar 13, 2026 3.35 3.45 3.10 3.30 3.30 245,625
Mar 12, 2026 3.71 3.81 3.33 3.37 3.37 278,618
Mar 11, 2026 3.73 4.00 3.51 3.81 3.81 601,516
Mar 10, 2026 2.99 3.64 2.99 3.60 3.60 425,037
Mar 9, 2026 3.19 3.47 3.06 3.09 3.09 285,442
Mar 6, 2026 3.05 3.38 3.05 3.23 3.23 249,306
Mar 5, 2026 2.82 3.12 2.76 3.12 3.12 360,025
Mar 4, 2026 2.70 2.91 2.60 2.81 2.81 169,031
Mar 3, 2026 2.62 2.75 2.54 2.63 2.63 125,189
Mar 2, 2026 2.68 2.83 2.66 2.71 2.71 107,078
Feb 27, 2026 2.81 2.84 2.67 2.76 2.76 96,053
Feb 26, 2026 3.23 3.27 2.78 2.87 2.87 259,325
Feb 25, 2026 2.90 3.32 2.85 3.29 3.29 677,309
Feb 24, 2026 2.76 3.31 2.68 2.86 2.86 502,924
Feb 23, 2026 2.79 3.04 2.60 2.77 2.77 1,093,218
Feb 20, 2026 2.26 2.80 2.19 2.78 2.78 832,147
Feb 19, 2026 2.16 2.33 2.06 2.27 2.27 197,838
Feb 18, 2026 2.11 2.19 2.09 2.15 2.15 259,123
Feb 17, 2026 2.22 2.23 2.07 2.11 2.11 102,619
Feb 13, 2026 2.27 2.37 2.18 2.23 2.23 127,071
Feb 12, 2026 2.10 2.30 2.01 2.24 2.24 243,715
Feb 11, 2026 2.14 2.16 1.95 2.09 2.09 199,275
Feb 10, 2026 2.15 2.15 2.00 2.10 2.10 238,409
Feb 9, 2026 2.15 2.17 2.04 2.15 2.15 202,870
Feb 6, 2026 2.07 2.21 1.98 2.17 2.17 221,753
Feb 5, 2026 2.26 2.26 1.97 2.02 2.02 355,725
Feb 4, 2026 2.30 2.35 2.16 2.30 2.30 250,302
Feb 3, 2026 2.09 2.35 2.05 2.29 2.29 725,637
Feb 2, 2026 1.85 2.07 1.85 2.03 2.03 124,410
Jan 30, 2026 1.87 1.93 1.80 1.85 1.85 142,899
Jan 29, 2026 1.99 2.05 1.80 1.90 1.90 894,896
Jan 28, 2026 2.15 2.15 1.97 1.97 1.97 96,875
Jan 27, 2026 2.02 2.20 1.99 2.12 2.12 207,152
Jan 26, 2026 2.01 2.10 1.90 2.03 2.03 182,901
Jan 23, 2026 2.20 2.21 1.99 2.02 2.02 213,976
Jan 22, 2026 1.81 2.30 1.81 2.21 2.21 652,469
Jan 21, 2026 1.84 1.95 1.82 1.82 1.82 237,903
Jan 20, 2026 1.83 1.96 1.76 1.84 1.84 311,016
Jan 16, 2026 2.10 2.10 1.78 1.81 1.81 1,444,307
Jan 15, 2026 2.27 2.27 2.09 2.15 2.15 307,387
Jan 14, 2026 2.18 2.30 2.12 2.26 2.26 318,178
Jan 13, 2026 2.17 2.26 2.05 2.24 2.24 366,150
Jan 12, 2026 2.61 2.67 2.10 2.20 2.20 1,466,459
Jan 9, 2026 2.78 2.82 2.63 2.63 2.63 633,841
Jan 8, 2026 2.80 2.99 2.74 2.76 2.76 358,420
Jan 7, 2026 2.64 2.87 2.56 2.83 2.83 978,090
Jan 6, 2026 2.48 2.64 2.41 2.56 2.56 210,816
Jan 5, 2026 2.71 2.79 2.37 2.44 2.44 433,935
Jan 2, 2026 2.90 2.90 2.60 2.73 2.73 362,202
Dec 31, 2025 2.81 2.95 2.75 2.90 2.90 219,203
Dec 30, 2025 2.95 2.98 2.64 2.84 2.84 529,913
Dec 29, 2025 2.42 3.00 2.36 2.94 2.94 1,558,206
Dec 26, 2025 2.26 2.48 2.21 2.45 2.45 267,187
Dec 24, 2025 2.20 2.33 2.20 2.23 2.23 107,876
Dec 23, 2025 2.23 2.25 2.12 2.19 2.19 313,950
Dec 22, 2025 2.17 2.38 2.09 2.26 2.26 571,639
Dec 19, 2025 1.94 2.15 1.90 2.14 2.14 621,834
Dec 18, 2025 1.98 2.02 1.90 1.92 1.92 169,933
Dec 17, 2025 2.03 2.17 1.87 1.95 1.95 885,495
Dec 16, 2025 1.90 2.06 1.79 1.99 1.99 993,779
Dec 15, 2025 1.72 1.98 1.71 1.94 1.94 1,107,556
Dec 12, 2025 1.61 1.72 1.60 1.71 1.71 341,632
Dec 11, 2025 1.65 1.69 1.61 1.63 1.63 160,902
Dec 10, 2025 1.71 1.72 1.62 1.65 1.65 235,251
Dec 9, 2025 1.47 1.70 1.46 1.70 1.70 631,359
Dec 8, 2025 1.50 1.51 1.45 1.46 1.46 206,711
Dec 5, 2025 1.56 1.56 1.43 1.46 1.46 292,779
Dec 4, 2025 1.34 1.55 1.34 1.54 1.54 292,099
Dec 3, 2025 1.33 1.40 1.29 1.38 1.38 264,283
Dec 2, 2025 1.55 1.55 1.34 1.34 1.34 477,845
Dec 1, 2025 1.67 1.67 1.51 1.55 1.55 253,843
Nov 28, 2025 1.66 1.70 1.60 1.68 1.68 370,862
Nov 26, 2025 1.59 1.68 1.53 1.67 1.67 296,741
Nov 25, 2025 1.42 1.60 1.32 1.59 1.59 802,919
Nov 24, 2025 1.66 1.66 1.40 1.40 1.40 577,729
Nov 21, 2025 1.61 1.69 1.52 1.67 1.67 429,907
Nov 20, 2025 1.65 1.68 1.50 1.60 1.60 296,794
Nov 19, 2025 1.65 1.70 1.61 1.67 1.67 248,090
Nov 18, 2025 1.63 1.73 1.55 1.68 1.68 682,597
Nov 17, 2025 1.52 1.69 1.46 1.65 1.65 701,398
Nov 14, 2025 1.47 1.54 1.42 1.52 1.52 572,420
Nov 13, 2025 1.48 1.62 1.42 1.51 1.51 817,338
Nov 12, 2025 1.38 1.48 1.34 1.47 1.47 701,291
Nov 11, 2025 1.27 1.40 1.21 1.35 1.35 611,652
Nov 10, 2025 1.19 1.29 1.17 1.26 1.26 516,156
Nov 7, 2025 1.33 1.33 1.19 1.19 1.19 1,091,496
Nov 6, 2025 1.38 1.51 1.34 1.35 1.35 1,153,246
Nov 5, 2025 1.65 1.65 1.38 1.39 1.39 3,057,459
Nov 4, 2025 2.12 2.20 1.53 1.76 1.76 26,527,612
Nov 3, 2025 1.58 4.22 1.43 3.98 3.98 34,568,268
Oct 31, 2025 1.56 1.64 1.51 1.59 1.59 111,378
Oct 30, 2025 1.57 1.61 1.47 1.57 1.57 141,482
Oct 29, 2025 1.57 1.62 1.50 1.58 1.58 177,015
Oct 28, 2025 1.72 1.72 1.54 1.54 1.54 125,501
Oct 27, 2025 1.66 1.72 1.57 1.71 1.71 269,705
Oct 24, 2025 1.50 1.63 1.49 1.62 1.62 227,500
Oct 23, 2025 1.59 1.59 1.47 1.50 1.50 115,873
Oct 22, 2025 1.60 1.68 1.44 1.58 1.58 380,209
Oct 21, 2025 1.29 1.65 1.23 1.64 1.64 1,229,009
Oct 20, 2025 1.17 1.30 1.16 1.29 1.29 179,764
Oct 17, 2025 1.30 1.35 1.16 1.19 1.19 174,111
Oct 16, 2025 1.36 1.42 1.27 1.31 1.31 106,710
Oct 15, 2025 1.31 1.40 1.29 1.36 1.36 211,243
Oct 14, 2025 1.27 1.32 1.21 1.30 1.30 76,337
Oct 13, 2025 1.25 1.29 1.20 1.25 1.25 89,120
Oct 10, 2025 1.39 1.41 1.15 1.26 1.26 547,323
Oct 9, 2025 1.45 1.46 1.32 1.40 1.40 177,765
Oct 8, 2025 1.41 1.50 1.36 1.42 1.42 240,968
Oct 7, 2025 1.45 1.46 1.38 1.44 1.44 58,521
Oct 6, 2025 1.47 1.53 1.33 1.46 1.46 261,835
Oct 3, 2025 1.44 1.53 1.42 1.47 1.47 282,000
Oct 2, 2025 1.51 1.59 1.40 1.44 1.44 235,964
Oct 1, 2025 1.47 1.63 1.44 1.51 1.51 266,377
Sep 30, 2025 1.37 1.50 1.25 1.44 1.44 340,673
Sep 29, 2025 1.91 1.91 1.21 1.37 1.37 1,488,428
Sep 26, 2025 1.22 1.51 1.19 1.50 1.50 734,955
Sep 25, 2025 1.16 1.23 1.16 1.22 1.22 112,836
Sep 24, 2025 1.04 1.22 1.04 1.17 1.17 181,076
Sep 23, 2025 1.10 1.15 1.02 1.03 1.03 299,659
Sep 22, 2025 0.9900 1.07 0.9900 1.01 1.01 180,259

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Prelude Therapeutics Incorporated Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at PRLD, per a recent SEC DEF 14A filing.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation